Home » Eli Lilly Receives Third Approval for Breast Cancer Treatment Verzenio
Eli Lilly Receives Third Approval for Breast Cancer Treatment Verzenio
Drugs Inspections and Audits
Eli Lilly’s Verzenio (abemaciclib) received FDA approval for a third indication — the combined use with an aromatase inhibitor as an initial endocrine-based therapy to treat postmenopausal women with HR+, HER2- advanced or metastatic breast cancer.
The drug received its initial approval in September, making it the first cyclin-dependent kinase 4 & 6 inhibitor approved for solo and combined use in treating metastatic breast cancer.
The expanded approval was supported by the efficacy and safety results of the MONARCH 3 clinical trial.